Literature DB >> 18275956

Comparison of the opioid receptor antagonist properties of naltrexone and 6 beta-naltrexol in morphine-naïve and morphine-dependent mice.

Mary F Divin1, M C Holden Ko, John R Traynor.   

Abstract

It has been proposed that on chronic morphine treatment the micro-opioid receptor becomes constitutively active, and as a consequence, the opioid withdrawal response arises from a reduction in the level of this constitutively active receptor. In support of this, the putative micro-opioid receptor inverse agonist naltrexone has been shown to precipitate more severe withdrawal behavior in mice than the putative neutral receptor antagonist 6 beta-naltrexol. In the present study naltrexone and 6 beta-naltrexol were compared in NIH Swiss mice to test the hypothesis that their differential ability to precipitate withdrawal is due to differences in their in vivo opioid receptor antagonist potencies caused by differential access to micro-opioid receptors in the central nervous system and not necessarily by intrinsic differences in their opioid receptor activity. In naïve mice both compounds had similar potencies to antagonize morphine-induced antinociception in the hot plate and warm-water tail-withdrawal assays when measured under equilibrium conditions and afforded similar calculated apparent in vivo micro-opioid receptor affinities. In morphine-dependent mice both compounds precipitated withdrawal jumping but naltrexone was between 10- and 100-fold more potent than 6 beta-naltrexol. A similar potency difference was seen for other withdrawal behaviors. Both naltrexone and 6 beta-naltrexol at 1 mg/kg reversed antinociception induced by the long-lasting micro-opioid receptor agonist BU72 in the warm-water tail-withdrawal assay, but antagonism by naltrexone was 6-fold more rapid in onset at equal doses. Since the compounds have similar affinity for the micro-opioid receptor in vivo, the results suggest that the differences observed between the ability of naltrexone and 6 beta-naltrexol to precipitate withdrawal in the mouse may be explained by differential onset of receptor antagonist action.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18275956      PMCID: PMC3010382          DOI: 10.1016/j.ejphar.2008.01.004

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  23 in total

1.  Influence of different benzodiazepines on the experimental morphine abstinence syndrome.

Authors:  R Maldonado; J A Micó; O Valverde; M C Saavedra; I Leonsegui; J Gibert-Rahola
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

2.  Butorphanol-mediated antinociception in mice: partial agonist effects and mu receptor involvement.

Authors:  H R Garner; T F Burke; C D Lawhorn; J M Stoner; W D Wessinger
Journal:  J Pharmacol Exp Ther       Date:  1997-09       Impact factor: 4.030

3.  In vivo characterization of 6beta-naltrexol, an opioid ligand with less inverse agonist activity compared with naltrexone and naloxone in opioid-dependent mice.

Authors:  Kirsten M Raehal; John J Lowery; Castigliano M Bhamidipati; Ryan M Paolino; Jennifer R Blair; Danxin Wang; Wolfgang Sadée; Edward J Bilsky
Journal:  J Pharmacol Exp Ther       Date:  2005-02-16       Impact factor: 4.030

4.  Differentiation of kappa opioid agonist-induced antinociception by naltrexone apparent pA2 analysis in rhesus monkeys.

Authors:  M C Ko; E R Butelman; J R Traynor; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

Review 5.  Basal opioid receptor activity, neutral antagonists, and therapeutic opportunities.

Authors:  Wolfgang Sadée; Danxin Wang; Edward J Bilsky
Journal:  Life Sci       Date:  2004-12-08       Impact factor: 5.037

6.  Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence.

Authors:  Ellen A Walker; Steven N Sterious
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

7.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

8.  Synthesis and opioid receptor affinity of a series of aralkyl ethers of 6 alpha- and 6 beta-naltrexol.

Authors:  T D Nelson; R D Davis; W L Nelson
Journal:  J Med Chem       Date:  1994-12-09       Impact factor: 7.446

9.  Serum time course of naltrexone and 6 beta-naltrexol levels during long-term treatment in drug addicts.

Authors:  A Ferrari; M Bertolotti; A Dell'Utri; U Avico; E Sternieri
Journal:  Drug Alcohol Depend       Date:  1998-11-01       Impact factor: 4.492

10.  Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence.

Authors:  Z Wang; E J Bilsky; F Porreca; W Sadée
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

View more
  11 in total

1.  Shadows across mu-Star? Constitutively active mu-opioid receptors revisited.

Authors:  Mark Connor
Journal:  Br J Pharmacol       Date:  2009-04       Impact factor: 8.739

2.  Role of meningeal mast cells in intrathecal morphine-evoked granuloma formation.

Authors:  Tony L Yaksh; Jeffery W Allen; Samantha L Veesart; Kjersti A Horais; Shelle A Malkmus; Miriam Scadeng; Joanne J Steinauer; Steve S Rossi
Journal:  Anesthesiology       Date:  2013-03       Impact factor: 7.892

3.  Intermittent marijuana use is associated with improved retention in naltrexone treatment for opiate-dependence.

Authors:  Wilfrid Noel Raby; Kenneth M Carpenter; Jami Rothenberg; Adam C Brooks; Huiping Jiang; Maria Sullivan; Adam Bisaga; Sandra Comer; Edward V Nunes
Journal:  Am J Addict       Date:  2009 Jul-Aug

4.  Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.

Authors:  M F Divin; F A Bradbury; F I Carroll; J R Traynor
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

5.  The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity.

Authors:  Sunil Sirohi; Shveta V Dighe; Priyanka A Madia; Byron C Yoburn
Journal:  J Pharmacol Exp Ther       Date:  2009-05-12       Impact factor: 4.030

6.  Role of the guanine nucleotide binding protein, Gαo, in the development of morphine tolerance and dependence.

Authors:  Jennifer T Lamberts; Lisa D Rosenthal; Emily M Jutkiewicz; John R Traynor
Journal:  Psychopharmacology (Berl)       Date:  2017-10-03       Impact factor: 4.530

7.  Relative potency of the opioid antagonists naloxone and 6-alpha-naloxol to precipitate withdrawal from acute morphine dependence varies with time post-antagonist.

Authors:  Gery Schulteis; David Chiang; Clay Archer
Journal:  Pharmacol Biochem Behav       Date:  2008-11-24       Impact factor: 3.533

8.  Analgesic tone conferred by constitutively active mu opioid receptors in mice lacking β-arrestin 2.

Authors:  Hoa Lam; Matthew Maga; Amynah Pradhan; Christopher J Evans; Nigel T Maidment; Tim G Hales; Wendy Walwyn
Journal:  Mol Pain       Date:  2011-04-12       Impact factor: 3.395

9.  Enhanced Intranasal Absorption of Naltrexone by Dodecyl Maltopyranoside: Implications for the Treatment of Opioid Overdose.

Authors:  Philip Krieter; Shwe Gyaw; C Nora Chiang; Roger Crystal; Phil Skolnick
Journal:  J Clin Pharmacol       Date:  2019-01-30       Impact factor: 3.126

10.  Isobolographic analysis of the opioid-opioid interactions in a tonic and a phasic mouse model of induced nociceptive pain.

Authors:  Hugo F Miranda; Viviana Noriega; Pilar Zanetta; Juan Carlos Prieto; Juan Carlos Prieto-Rayo; Nicolás Aranda; Fernando Sierralta
Journal:  J Biomed Sci       Date:  2014-07-15       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.